Search

Displaying results 671 - 680 of 4860 in total
  1. Drug

    Torasemide

    go.drugbank.com/drugs/DB00214
    ApprovedInvestigational

    [A174463] Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent.[A319] Torasemide was first approved for clinical use by the FDA in 1993.[L5257]

  2. Drug

    Amuvatinib

    go.drugbank.com/drugs/DB12742
    Investigational

    Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3.

  3. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.

  4. Drug

    Arginine

    go.drugbank.com/drugs/DB00125
    ApprovedInvestigationalNutraceutical

    An essential amino acid that is physiologically active in the L-form.

    Mixtures: OLEUNOR 4,4% mit Elektrolyten Emulsion zur Infusion, OLEUNOR 5,7% mit Elektrolyten Emulsion zur Infusion
  5. Drug

    Palbociclib

    go.drugbank.com/drugs/DB09073
    ApprovedInvestigational

    It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. … [L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male

  6. Drug

    Camphor

    go.drugbank.com/drugs/DB01744
    ApprovedInvestigationalWithdrawn

    It is used topically as a skin antipruritic and as an anti-infective agent. … It appears in the list of drug products withdrawn or removed from the market for safety or effectiveness.

    Mixtures: Ken- Ku Oil Cap Pancor Mas, MIST CARMINATIVE
  7. Drug

    Equine Botulinum Neurotoxin F Immune FAB2

    go.drugbank.com/drugs/DB13901
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes F in adults and pediatric patients.

  8. Drug

    Equine Botulinum Neurotoxin E Immune FAB2

    go.drugbank.com/drugs/DB13897
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes E in adults and pediatric patients.

  9. Drug

    Equine Botulinum Neurotoxin C Immune FAB2

    go.drugbank.com/drugs/DB13898
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes C in adults and pediatric patients.

  10. Target

    2-methylisocitrate lyase

    go.drugbank.com/bio_entities/BE0001259
    TargetEscherichia coli (strain K12)

    Involved in the catabolism of short chain fatty acids (SCFA) via the 2-methylcitrate cycle I (propionate degradation route). Catalyzes the thermodynamically favored C-C bond cleavage of (2R,3S)-2-methylisocitrate to yield pyruvate and su...

    Synonyms: 2-MIC